Skip to content

Clinical trials

Observational Alzheimer Disease trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Alzheimer Disease Phase: Observational Country / region: France Clear all

93 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20042
20071
20097
20107
20116
20122
20132
20144
20152
20163
20174
20184
20196
20201
20217
20224
20238
20248
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed50
Recruiting23
Unknown status11
Terminated4
Not yet recruiting3
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris14
University Hospital, Angers7
University Hospital, Bordeaux7
Central Hospital, Nancy, France6
Centre Hospitalier Universitaire de Nice5
Institut National de la Santé Et de la Recherche Médicale, France4
University Hospital, Lille4
Amoneta Diagnostics SAS3
Centre Hospitalier Universitaire de Saint Etienne3
University Hospital, Caen3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Alzheimer Disease93
Dementia19
Cognitive Dysfunction13
Mental Disorders7
Frontotemporal Dementia6
Neurocognitive Disorders6
Cognition Disorders5
Lewy Body Disease5
Neurodegenerative Diseases5
Gait Apraxia4

Trials

Showing 1 to 25 of 93. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.